| Literature DB >> 35531119 |
Valakunja Harikrishna Ganaraja1, Vikram V Holla1, Albert Stezin1,2, Nitish Kamble1, Ravi Yadav1, Meera Purushottam3, Sanjeev Jain3, Pramod Kumar Pal1.
Abstract
Introduction: Spinocerebellar ataxia type-12 (SCA12) is a rare form of SCA, most commonly reported from the Indian Agarwal and related families. In this study we describe the clinical, genetic, and radiological characteristics of a sizeable cohort of genetically proven SCA12.Entities:
Keywords: Ataxia; Spinocerebellar ataxia type 12; Tremors; Trinucleotide repeats
Mesh:
Substances:
Year: 2022 PMID: 35531119 PMCID: PMC9029677 DOI: 10.5334/tohm.686
Source DB: PubMed Journal: Tremor Other Hyperkinet Mov (N Y) ISSN: 2160-8288
Demographic profile of patients with SCA 12.
|
| ||
|---|---|---|
| TOTAL NUMBER | PERCENTAGE | |
|
| ||
| Total number of patients | 49 | 100% |
|
| ||
| Male: Female | 34:15 | |
|
| ||
| Place of residence | ||
|
| ||
| Orissa | 10 | 20% |
|
| ||
| West Bengal | 10 | 20% |
|
| ||
| Karnataka | 7 | 14% |
|
| ||
| Bihar | 4 | 8% |
|
| ||
| Jharkhand | 4 | 8% |
|
| ||
| Madhya Pradesh | 3 | 6% |
|
| ||
| Maharashtra | 2 | 4% |
|
| ||
| Assam | 2 | 4% |
|
| ||
| Tamil Nadu | 2 | 4% |
|
| ||
| Chhattisgarh | 1 | 2% |
|
| ||
| Delhi | 1 | 2% |
|
| ||
| Rajasthan | 1 | 2% |
|
| ||
| Uttar Pradesh | 1 | 2% |
|
| ||
| Uttarakhand | 1 | 2% |
|
| ||
| Community | ||
|
| ||
| | 39 | 79.6% |
|
| ||
| Unclear/not disclosed | 5 | 10.2% |
|
| ||
| Non- | 5 | 10.2% |
|
| ||
| Urban: Rural | 42:7 | |
|
| ||
| Positive family history | 46 | 93.8% |
|
| ||
| Co-morbidities | ||
|
| ||
| DM | 13 | 26.5% |
|
| ||
| HTN | 13 | 26.5% |
|
| ||
| Hypothyroidism | 5 | 10.2% |
|
| ||
| IHD | 2 | 4% |
|
| ||
| Asthma | 1 | 2% |
|
| ||
Abbreviations: DM- diabetes mellitus, HTN- hypertension, IHD- ischemic heart disease.
Ataxic and non ataxic features of patients with SCA 12.
|
| ||
| Age at onset: | 46.38 ± 11.7 years | |
|
| ||
| Duration of illness: | 9.20 ± 9.5 years | |
|
| ||
| Age at presentation: | 53.16 ± 12.78 years | |
|
| ||
| Symptom at onset: | Total numbers | % |
|
| ||
| Tremors | 36 | 73.5% |
|
| ||
| Ataxia | 9 | 18.4% |
|
| ||
| Myoclonus | 3 | 6.1% |
|
| ||
| Behavioural changes | 1 | 2% |
|
| ||
| Symptom at presentation | ||
|
| ||
| Tremors | 47 | 95.9% |
|
| ||
| Ataxia | 36 | 73.5% |
|
| ||
| Cognitive dysfunction | 11 | 22.4% |
|
| ||
| Urinary disturbance | 10 | 20.4% |
|
| ||
| Psychiatric disturbance | 4 | 8.1% |
|
| ||
| Myoclonus | 3 | 6% |
|
| ||
| Extrapyramidal symptoms | 3 | 6% |
|
| ||
| Sensory Symptoms | 1 | 2% |
|
| ||
|
| 47 | 95.9% |
|
| ||
| Duration | 7.13 ± 4.28 years | |
|
| ||
| Side and site at onset | ||
|
| ||
| Right UL | 26 | 53.1% |
|
| ||
| Bilateral | 17 | 34.7% |
|
| ||
| Left UL | 2 | 4.1% |
|
| ||
| Head | 2 | 4.1% |
|
| ||
| Side of appendicular tremor at presentation | ||
|
| ||
| Bilateral | 42 | 85.7% |
|
| ||
| Right UL | 2 | 4.1% |
|
| ||
| Head | 2 | 4.1% |
|
| ||
| Left UL | 1 | 2% |
|
| ||
| Type of tremor | ||
|
| ||
| Postural | 43 | 87.7% |
|
| ||
| Intentional | 28 | 57.1% |
|
| ||
| Kinetic | 13 | 26.5% |
|
| ||
| Rest | 18 | 36.7% |
|
| ||
| Head tremor | 27 | 55.1% |
|
| ||
| Voice tremor | 21 | 42.8% |
|
| ||
| Jaw tremor | 5 | 10.2% |
|
| ||
| Tongue tremor | 5 | 10.2% |
|
| ||
|
| 36 | 73.5% |
|
| ||
| Duration | 4.88 ± 3.86 years | |
|
| ||
| Ataxia on examination | 44 | 89.8% |
|
| ||
| Impaired tandem gait | 44 | 89.8% |
|
| ||
| Dysmetria | 37 | 75.5% |
|
| ||
| Dyssynergia | 33 | 67.3% |
|
| ||
| Dysdiadokinesia | 33 | 67.3% |
|
| ||
| Dysarthria | 28 | 57.1% |
|
| ||
| Saccadic abnormality | 13 | 26.5% |
|
| ||
| Broken pursuits | 14 | 28.6% |
|
| ||
| Nystagmus | 10 | 20.4% |
|
| ||
| Need for walking aid | 8 | 18.2% |
|
| ||
|
| ||
|
| ||
| Hyperreflexia | 23 | 46.9% |
|
| ||
| Spasticity | 9 | 18.4% |
|
| ||
| Extensor plantar | 4 | 8.2% |
|
| ||
|
| ||
|
| ||
| Rigidity | 7 | 14.2% |
|
| ||
| Bradykinesia | 15 | 30.6% |
|
| ||
| Chorea | 1 | 2% |
|
| ||
| Dystonia | 4 | 8.2% |
|
| ||
Abbreviations: UL- Upper Limb, DTR- deep Tendon Reflexes.
Profile of medications use among patients with SCA 12.
|
| ||
|---|---|---|
| MEDICATIONS TRIED | NUMBER OF PATIENTS | PERCENTAGE (%) |
|
| ||
| Amantadine (100 – 300mg/day) | 26 | 53% |
|
| ||
| Propranolol (20 – 60 mg/day) | 26 | 53% |
|
| ||
| Benzodiazepines | 21 | 42.8% |
|
| ||
| Primidone (250 – 500mg/day) | 14 | 28.5% |
|
| ||
| L Dopa (400 – 600mg/day) | 5 | 10.2% |
|
| ||
| Trihexyphenidyl (6 – 12 mg/day) | 3 | 6.1% |
|
| ||
| Baclofen (20 – 40 mg/day) | 2 | 4% |
|
| ||
|
| ||
|
| ||
| One | 13 | 26.5% |
|
| ||
| Two | 26 | 53% |
|
| ||
| Three | 6 | 12.1% |
|
| ||
| Four | 4 | 8.2% |
|
| ||